Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | ME2 | P23368 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29822805 | 0.83 | BACE1 (0.49) | BACE1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL9850097 | 0.81 | NCOA1 (0.48) | KMT2AKDM4EMAPK1ALDH1A1LMNA | |
| SCHEMBL8595040 | 0.81 | NOTUM (0.43) | MAPTMEN1KMT2APKMLMNA | |
| SCHEMBL8552206 | 0.79 | PTGS1 (0.41) | PTGS1CYP2C9 | |
| SCHEMBL7351176 | 0.78 | CYP19A1 (0.55) | MAPTMEN1KMT2AKDM4EPKM | |
| SCHEMBL30527899 | 0.77 | ALDH1A1 (0.41) | MAPTMEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL979621 | 0.77 | CFTR (0.43) | BACE1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL7350997 | 0.76 | HDAC4 (0.48) | MAPTKDM4ETDP1ALDH1A1CYP19A1 | |
| SCHEMBL30527856 | 0.76 | KMT2A (0.31) | KMT2A | |
| SCHEMBL30527907 | 0.76 | CYP1A2 (0.38) | MAPTKDM4EALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1441721-A2 | USE OF ENDOTHELIN RECEPTOR ANTAGONISTS IN THE TREATMENT OF TUMOUR DISEASES | MERCK PATENT GmbH (DE) | 2004-08-04 | — | — | EP | claimed |
| WO-2003039539-A2 | USE OF ENDOTHELIN RECEPTOR ANTAGONISTS IN THE TREATMENT OF TUMOUR DISEASES | MERCK PATENT GMBH (DE) | 2003-05-15 | — | — | WO | claimed |
| EP-0714391-A1 | SUBSTITUTED 2(5H)FURANONE, 2(5H)THIOPHENONE AND 2(5H)PYRROLONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-06-05 | — | — | EP | claimed |
| CN-117304148-A | 3, 4-disubstituted gamma-butyrolactone derivative, preparation method thereof and application of 3, 4-disubstituted gamma-butyrolactone derivative in preparation of antitumor drugs | 烟台大学 | 2023-12-29 | — | — | CN | disclosed |
| CN-113735804-B | Synthesis method of butenolide compound | 浙江大学 | 2023-07-18 | — | — | CN | disclosed |
| US-8481534-B2 | 5- and 6-membered heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110183976-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | FMR LLC | 2011-07-28 | — | — | US | disclosed |
| EP-1441721-A2 | USE OF ENDOTHELIN RECEPTOR ANTAGONISTS IN THE TREATMENT OF TUMOUR DISEASES | MERCK PATENT GmbH (DE) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003039539-A2 | USE OF ENDOTHELIN RECEPTOR ANTAGONISTS IN THE TREATMENT OF TUMOUR DISEASES | MERCK PATENT GMBH (DE) | 2003-05-15 | — | — | WO | disclosed |
| EP-0882030-A1 | 2,1,3-BENZOTHIA(OXA)DIAZOLE DERIVATIVES HAVING AN ENDOTHELIN RECEPTOR ANTAGONISTIC EFFECT | MERCK PATENT GmbH (DE) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998042702-A1 | ENDOTHELIN-RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 1998-10-01 | — | — | WO | disclosed |
| WO-1997030982-A1 | 2,1,3-BENZOTHIA(OXA)DIAZOLE DERIVATIVES HAVING AN ENDOTHELIN RECEPTOR ANTAGONISTIC EFFECT | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1997-08-28 | — | — | WO | disclosed |
| WO-1997008169-A1 | FURANONE ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-03-06 | — | — | WO | disclosed |
| EP-0714391-A1 | SUBSTITUTED 2(5H)FURANONE, 2(5H)THIOPHENONE AND 2(5H)PYRROLONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183976-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | ACHE, PDE7A, PDE5A | BACE1 43/4885MAPT 256/4885MEN1 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.